Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T17:02:14.350Z.
Calculation as of: 2026-10-06T17:02:14.350Z.
Quote observation: 2026-10-06T17:00:48.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6da64a8b1a2a274dcb8686c6d20e6c80d542b1d2a14b58c5ff35188fa74041c0
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$5.98M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6.53M
EV/EBITDA Ratio
N/A
TTM Avg
34.26x
3Y Avg
34.26x
5Y Avg
668.76x
Market Cap
$5.79M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Femasys Inc. (FEMY) | $6.28M | N/A | N/A | N/A | N/A |
| Scienture Holdings, Inc. (SCNX)vs › | $6.01M | N/A | N/A | N/A | N/A |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.45M | N/A | N/A | N/A | N/A |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $5.98M | N/A | N/A | N/A | N/A |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $6.06M | N/A | N/A | N/A | N/A |
| Biomerica, Inc. (BMRA)vs › | $6.54M | N/A | 96.60x | 88.71x | 504.98x |
| Lucyd, Inc (LUCY)vs › | $5.82M | N/A | N/A | N/A | N/A |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.53M | N/A | 34.26x | 34.26x | 668.76x |
| Sonoma Pharmaceuticals, Inc. (SNOA)vs › | $5.79M | N/A | N/A | N/A | N/A |
| enVVeno Medical Corporation (NVNO)vs › | $5.77M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
